Search for a report

GLOBAL CANCER BIOMARKER MARKET FORECAST 2019-2027

  • You are here:
  • Home
  • Downloads
  • GLOBAL CANCER BIOMARKER MARKET FORECAST 2019-2027

GLOBAL CANCER BIOMARKER MARKET FORECAST 2019-2027

The global cancer biomarker market is anticipated to grow at a CAGR of 11.32% between 2019 and 2027. The cancer biomarkers are traceable substances, molecules, or a physical event that indicate the existence of cancerous cells in the body. The cancer biomarker market is mainly driven by the following factors: Adoption of western lifestyles in the developing regions. Encouragement for biomarker development by FDA. Growth in the importance of biological and targeted drug therapies

GLOBAL CANCER BIOMARKER MARKET FORECAST 2019-2027

Cancer Biomarker Market by Profiling Technology (Omic Technology (Genomics, Proteomics, Other Omic Technologies, Imaging Technologies, Immunoassays, Cytogenetic-based Tests) by Biomarker (Genetic Biomarkers, Protein Biomarkers, Glyco Biomarkers) by Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Others Cancer Type) by Application (Diagnostics, Drug Discovery and Development, Prognostics, Risk Assessment, Other Application) & by Geography

Request free sample

The global cancer biomarker market is anticipated to grow at a CAGR of 11.32% between 2019 and 2027. The cancer biomarkers are traceable substances, molecules, or a physical event that indicate the existence of cancerous cells in the body. The cancer biomarker market is mainly driven by the following factors:

  • Adoption of western lifestyles in the developing regions
  • Encouragement for biomarker development by FDA
  • Growth in the importance of biological and targeted drug therapies
  • Growing prevalence on the research of cancer biomarkers
  • Technological advancements
  • Improved precision and speed of diagnosis
  • High investment through government and private funds in cancer-related research
  • Development of highly specific drugs
  • Growing personalized medicine and companion diagnostics

Cancer Biomarker MarketTo know more about this report, request a free sample copy

The important drivers increasing growth in the global cancer biomarker market is the growing prevalence on the research of cancer biomarkers and growing personalized medicine and companion diagnostics. The rising research projects related to cancer biomarkers is anticipated to improve the clinical efficacy and to invent new techniques for the detection of cancer in the initial stage. The personalized medicines hold tremendous opportunities for the growth of the cancer biomarkers market by developing suitable treatment solutions as per an individual’s need.

Cancer profiling technology and applications are useful in cancer biomarker. Profiling technology includes Omic Technology, Imaging Technologies, Immunoassays and Cytogenetic-Based Tests. Whereas, applications segment comprises diagnostics, drug discovery and development, prognostics, risk assessment and other application. Omic technologies are high-throughput technologies utilized to measure and evaluate the different types of cellular molecules. Imaging biomarkers are important tools used to detect and characterize cancer as well as to monitor the response of the therapy. Immunoassay testing has been used to diagnose various infectious diseases, oncological detection, HIV/AIDS virus detection, and others. Diagnostic biomarkers are used to determine the presence or absence of cancer. Cancer biomarkers are used for the disease prognosis, which is carried out after the diagnosis of cancer. Cancer biomarkers are quantitative indicators used for evaluating various aspects of disease progression.

The low estimated rate of successful clinical trials of biomarkers and the high cost of drug development are the major factors hampering the cancer biomarker market. There are high investment and low benefit-cost ratio related to the growth of cancer biomarkers which is also creating major limitations to the market. Also, the cost of new drug development is very high and not affordable for small and medium-sized organizations, which limits their entry into the market.

The global cancer biomarker market segments include profiling, biomarker, cancer type and application.

Profiling is segmented into:

  • Omics technology
    • Genomics
      • Next-generation sequencing (NGS)
      • Microarray
      • Polymerase chain reaction (PCR)
    • Proteomics
      • Mass spectrometry
      • 2D gel electrophoresis
      • Protein microarray technology
      • Antibody array technology
      • Peptide array technology
    • Other omic technologies
      • Metabolomics
      • Glycomics
    • Imaging technologies
      • Magnetic resonance imaging (MRI)
      • Positron emission tomography (PET)
      • Computed tomography
      • Mammography
      • Ultrasound
    • Immunoassays
      • Immunohistochemistry (IHC) tests
      • Enzyme-linked immunosorbent assay (ELISA)
      • Flow cytometry
    • Cytogenetic-based tests
      • In situ hybridization
      • Others cytogenetic-based tests

Biomarker is segmented into:

  • Genetic biomarkers
  • Protein biomarkers
  • Glyco biomarkers

Cancer type is segmented into:

  • Lung cancer
  • Breast cancer
  • Colorectal cancer
  • Prostate cancer
  • Stomach cancer
  • Others cancer type

Application is segmented into:

  • Diagnostics
  • Drug discovery and development
  • Prognostics
  • Risk assessment
  • Other application

This report covers the present market conditions and the growth prospects of the global cancer biomarker market for 2019-2027, considering the revenue generated through the sales of cancer biomarker tools for profiling, biomarker, cancer type, and application to calculate the market size by considering 2018 as the base year.

Geographically, the global cancer biomarker market has been segmented on the basis of four major regions, which include:

The cancer biomarker market in North America is expected to hold the largest share by 2027 due to developed economies such as the United States and Canada and the high prevalence of cancer. The region is also making investments considering the detection and diagnosis of cancer. The United States is the leading country in the North America cancer biomarkers market. The United States is the dominating market due to increased demand for investment in research and development, the growing prevalence of cancer and medical tourism.

On the other hand, the Asia-Pacific market is anticipated to be the fastest-growing region in the cancer biomarker market. The growing population in countries such as China and India, rising investments by public and private sectors in the cancer diagnosis and treatment as well as the growing prevalence rate of cancer in the Asia-Pacific region is expanding the cancer biomarkers market in the Asia-Pacific region. In addition, the rise in medical tourism considering the cancer diagnosis and treatment is also impacting the market growth in the region.

The cancer biomarker market is segmented into biomarker which is sub-divided into Genetic Biomarkers, Protein Biomarkers & Glyco Biomarkers. The market is segmented on the basis of cancer type which is sub-divided into Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer & Others Cancer Type.

The major market players in the global cancer biomarker market are:

  • Abbott Laboratories
  • Roche Diagnostics Ltd.
  • Qiagen NV.
  • Beckamn Coulter
  • Aureon Laboratories Inc.

Company Profiles covers analysis of important players.

Abbott Laboratories (Abbott) is a U.S. based company, headquartered in Illinois. The company discovers, develop, manufacture and sell a line of health care products. The company majorly operates in four business segments: vascular products, nutritional products, diagnostic products, and established pharmaceutical products. Aureon Biosciences, Inc. is the United States based life sciences company having headquarters in Yonkers, New York. The company offers advanced personalized and predictive cancer treatment options. The prognostic tests include Prostate Px and Post-Op Px. The company prognostic tools offer risk assessment at diagnosis and after surgery.

Key Findings of the global cancer biomarker market:

  • Omics technology generated the highest revenue in terms of profiling technology
  • Glyco biomarkers are the fastest growing cancer biomarkers
  • Breast cancer holds the largest market share in terms of cancer type
  • Diagnostics application is the majorly used cancer biomarker application
  1. RESEARCH SCOPE
    • STUDY GOALS
    • SCOPE OF THE MARKET STUDY
    • WHO WILL FIND THIS REPORT USEFUL?
    • STUDY AND FORECASTING YEARS
  2. RESEARCH METHODOLOGY
    • SOURCES OF DATA
      • SECONDARY DATA
      • PRIMARY DATA
    • TOP DOWN APPROACH
    • BOTTOM-UP APPROACH
    • DATA TRIANGULATION
  3. EXECUTIVE SUMMARY
    • MARKET SUMMARY
    • KEY FINDINGS
      • OMIC TECHNOLOGY GENERATED THE HIGHEST REVENUE IN TERMS OF PROFILING TECHNOLOGY
      • GLYCO BIOMARKERS ARE THE FASTEST GROWING CANCER BIOMARKERS
      • BREAST CANCER HOLDS THE LARGEST MARKET SHARE IN TERMS OF CANCER TYPE
      • DIAGNOSTICS APPLICATION IS THE MAJORLY USED CANCER BIOMARKER APPLICATION
  1. MARKET DYNAMICS
    • MARKET SCOPE & DEFINITION
    • MARKET DRIVERS
      • ADOPTION OF WESTERN LIFESTYLES IN DEVELOPING REGIONS
      • GROWING PREVALENCE ON RESEARCH OF CANCER BIOMARKERS
      • ENCOURAGEMENT FOR BIOMARKER DEVELOPMENT BY FDA
      • IMPROVED PRECISION AND SPEED OF DIAGNOSIS
      • HIGH INVESTMENT THROUGH GOVERNMENT AND PRIVATE FUNDS IN CANCER RELATED RESEARCH
      • DEVELOPMENT OF HIGHLY SPECIFIC DRUGS
      • GROWTH IN IMPORTANCE OF BIOLOGICAL AND TARGETED DRUG THERAPIES
      • TECHNOLOGICAL ADVANCEMENTS
      • GROWING PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS
    • MARKET RESTRAINTS
      • POOR COMPENSATION STRUCTURES
      • LOW ESTIMATED RATE OF SUCCESSFUL CLINICAL TRIALS OF BIOMARKERS
      • TECHNICAL ISSUES RELATED TO CANCER BIOMARKERS
      • HIGH COST OF DRUG DEVELOPMENT
      • UNCLEAR GOVERNMENT REGULATION AND REIMBURSEMENT POLICIES
    • MARKET OPPORTUNITIES
      • WIDE OPPORTUNITY TO GROW IN PERSONALIZED MEDICATION
      • SUPPORTS ON BIOMARKERS TEST
      • GROWING NUMBER OF CANCER PATIENTS AND GROWING MEDICAL TOURISM IN EMERGING ECONOMIES
      • ADVANCEMENT OF CANCER DRUGS RESEARCH
    • MARKET CHALLENGES
      • LACKING ACCEPTANCE OF THE CANCER BIOMARKER
      • UNFAVORABLE COMPENSATION SITUATION
      • HIGH COST OF DEVELOPING COMPANION DIAGNOSTICS
      • RIGOROUS REGULATORY AGENDA
      • DEARTH OF SKILFUL WORKERS
  1. MARKET BY PROFILING TECHNOLOGY
    • OMIC TECHNOLOGY
      • GENOMICS
        • NEXT-GENERATION SEQUENCING (NGS)
        • MICROARRAY
        • POLYMERASE CHAIN REACTION (PCR)
      • PROTEOMICS
        • MASS SPECTROMETRY
        • 2D GEL ELECTROPHORESIS
        • PROTEIN MICROARRAY TECHNOLOGY
        • ANTIBODY ARRAY TECHNOLOGY
        • PEPTIDE ARRAY TECHNOLOGY
      • OTHER OMIC TECHNOLOGIES
        • METABOLOMICS
        • GLYCOMICS
      • IMAGING TECHNOLOGIES
        • MAGNETIC RESONANCE IMAGING (MRI)
        • POSITRON EMISSION TOMOGRAPHY (PET)
        • COMPUTED TOMOGRAPHY
        • MAMMOGRAPHY
        • ULTRASOUND
      • IMMUNOASSAYS
        • IMMUNOHISTOCHEMISTRY (IHC) TESTS
        • ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
        • FLOW CYTOMETRY
      • CYTOGENETIC-BASED TESTS
        • IN SITU HYBRIDIZATION
        • OTHERS CYTOGENETIC-BASED TESTS
  1. MARKET BY BIOMARKER
    • GENETIC BIOMARKERS
    • PROTEIN BIOMARKERS
    • GLYCO BIOMARKERS
  2. MARKET BY CANCER TYPE
    • LUNG CANCER
    • BREAST CANCER
    • COLORECTAL CANCER
    • PROSTATE CANCER
    • STOMACH CANCER
    • OTHERS CANCER TYPE
  3. MARKET BY APPLICATION
    • DIAGNOSTICS
    • DRUG DISCOVERY AND DEVELOPMENT
    • PROGNOSTICS
    • RISK ASSESSMENT
    • OTHER APPLICATION
  4. KEY ANALYTICS
    • PORTER’S FIVE FORCE ANALYSIS
      • THREAT OF NEW ENTRANTS
      • THREAT OF SUBSTITUTE PRODUCT
      • BARGAINING POWER OF BUYER
      • BARGAINING POWER OF SUPPLIERS
      • INTENSITY OF COMPETITIVE RIVALRY
    • KEY BUYING CRITERIA
      • PRICING
      • EFFICACY
      • APPLICATION AND EFFECTIVENESS
    • PATENT ANALYSIS
    • ONCOLOGY DRUGS APPROVALS BY THE FDA
    • OPPORTUNITY MATRIX
  5. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • THE UNITED STATES
      • CANADA
    • EUROPE
      • GERMANY
      • THE UNITED KINGDOM
      • FRANCE
      • ITALY
      • SPAIN
      • REST OF EUROPE
    • ASIA PACIFIC
      • CHINA
      • INDIA
      • JAPAN
      • SOUTH KOREA
      • AUSTRALIA
      • REST OF APAC
    • REST OF WORLD
      • LATIN AMERICA
      • MIDDLE EAST AND AFRICA
  1. COMPETITIVE LANDSCAPE
    • MARKET SHARE ANALYSIS
    • COMPANY PROFILES
      • ABBOTT LABORATORIES
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • AGENDIA N.V.
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • AGILENT TECHNOLOGIES, INC.
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • AUREON BIOSCIENCES, INC
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • ASTELLAS PHARMA INC.
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • BECKMAN COULTER
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • BECTON DICKINSON AND COMPANY
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • BRISTOL-MYERS SQUIBB
        • COMPANY PROFILES
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • CELGENE CORPORATION
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • CLARIENT, INC. (ACQUIRED BY NEOGENOMICS LABORATORIES)
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • DIADEXUS INC. (ACQUIRED BY DIAZYME LABORATORIES)
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • ILLUMINA, INC.
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • ROCHE DIAGNOSTICS LTD
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES
      • SANOFI
        • COMPANY OVERVIEW
        • PRODUCTS PORTFOLIO
        • SWOT ANALYSIS
        • STRATEGIC INITIATIVES
      • QIAGEN N.V.
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SCOT ANALYSIS
        • STRATEGIC INITIATIVES

 

TABLE LIST

TABLE  1      GLOBAL CANCER BIOMARKER MARKET BY REGION 2019-2027 ($ MILLION)

TABLE  2      RECENT RESEARCH ON BIOMARKERS

TABLE  3      LIST OF FDA APPROVED PROTEIN CANCER BIOMARKERS

TABLE  4      POTENTIAL CLINICAL USE OF  CANCER BIOMARKERS

TABLE  5      MEDICAL TOURISM PRICES IN US DOLLAR

TABLE  6      GLOBAL CANCER BIOMARKER MARKET BY PROFILING TECHNOLOGY 2019-2027 ($ MILLION)

TABLE  7      GLOBAL OMIC TECHNOLOGY MARKET BY REGION 2019-2027 ($ MILLION)

TABLE  8      GLOBAL OMIC TECHNOLOGY MARKET BY TYPE 2019-2027 ($ MILLION)

TABLE  9      GLOBAL GENOMICS MARKET BY TYPE 2019-2027 ($ MILLION)

TABLE  10    GLOBAL PROTEOMICS MARKET BY TYPE 2019-2027 ($ MILLION)

TABLE  11    GLOBAL OTHER OMIC TECHNOLOGIES MARKET BY TYPE 2019-2027 ($ MILLION)

TABLE  12    GLOBAL IMAGING TECHNOLOGIES MARKET BY REGION 2019-2027 ($ MILLION)

TABLE  13    GLOBAL IMAGING TECHNOLOGIES MARKET BY TYPE 2019-2027 ($ MILLION)

TABLE  14    GLOBAL IMMUNOASSAYS MARKET BY REGION 2019-2027 ($ MILLION)

TABLE  15    GLOBAL IMMUNOASSAYS MARKET BY TYPE 2019-2027 ($ MILLION)

TABLE  16    GLOBAL CYTOGENETICS-BASED TESTS MARKET BY REGION 2019-2027 ($ MILLION)

TABLE  17    GLOBAL CYTOGENETICS-BASED TESTS  MARKET BY TYPE 2019-2027 ($ MILLION)

TABLE  18    GLOBAL CANCER BIOMARKER MARKET BY BIOMARKER 2019-2027 ($ MILLION)

TABLE  19    GLOBAL GENETIC BIOMARKERS MARKET BY REGION 2019-2027 ($ MILLION)

TABLE  20    GLOBAL PROTEIN BIOMARKERS MARKET BY REGION 2019-2027 ($ MILLION)

TABLE  21    GLOBAL GLYCO BIOMARKERS MARKET BY REGION 2019-2027 ($ MILLION)

TABLE  22    GLOBAL CANCER BIOMARKER MARKET BY CANCER TYPE 2019-2027 ($ MILLION)

TABLE  23    GLOBAL LUNG CANCER MARKET BY REGION 2019-2027 ($ MILLION)

TABLE  24    GLOBAL BREAST CANCER MARKET BY REGION 2019-2027 ($ MILLION)

TABLE  25    GLOBAL COLORECTAL CANCER MARKET BY REGION 2019-2027 ($ MILLION)

TABLE  26    GLOBAL PROSTATE CANCER MARKET BY REGION 2019-2027 ($ MILLION)

TABLE  27    GLOBAL STOMACH CANCER MARKET BY REGION 2019-2027 ($ MILLION)

TABLE  28    GLOBAL OTHERS CANCER TYPE MARKET BY REGION 2019-2027 ($ MILLION)

TABLE  29    GLOBAL CANCER BIOMARKER MARKET BY APPLICATION 2019-2027 ($ MILLION)

TABLE  30    GLOBAL DIAGNOSTICS MARKET BY REGION 2019-2027 ($ MILLION)

TABLE  31    GLOBAL DRUG DISCOVERY AND DEVELOPMENT MARKET BY REGION 2019-2027 ($ MILLION)

TABLE  32    GLOBAL PROGNOSTICS MARKET BY REGION 2019-2027 ($ MILLION)

TABLE  33    GLOBAL RISK ASSESSMENT MARKET BY REGION 2019-2027 ($ MILLION)

TABLE  34    GLOBAL OTHER APPLICATION MARKET BY REGION 2019-2027 ($ MILLION)

TABLE  35    PATENT PRODUCTS WITH THE EXPIRY DATE

TABLE  36    PATENT PUBLICATIONS RELATED TO  BREAST CANCER 2017

TABLE  37    PATENT PUBLICATIONS RELATED TO  PROSTATE CANCER 2017

TABLE  38    PATENT PUBLICATIONS RELATED TO  LUNG CANCER 2017

TABLE  39    GLOBAL CANCER BIOMARKER MARKET BY REGION 2019-2027 ($ MILLION)

TABLE  40    NORTH AMERICA CANCER BIOMARKER MARKET BY COUNTRY 2019-2027 ($ MILLION)

TABLE  41    EUROPE CANCER BIOMARKER MARKET BY COUNTRY 2018-2026 ($ MILLION)

TABLE  42    ASIA PACIFIC CANCER BIOMARKER MARKET BY COUNTRY 2019-2027 ($ MILLION)

TABLE  43    STATE-WISE DISTRIBUTION OF CANCER IN INDIA

TABLE  44    ESTIMATED MOST COMMON CANCERS DIAGNOSED IN AUSTRALIA 2017

TABLE  45    REST OF WORLD CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

 

FIGURE LIST

FIGURE  1    NUMBER OF PEOPLE LIVING WITH CANCER ACROSS THE GLOBE FOR PERIOD 2012-2020 (MILLION)

FIGURE  2    GLOBAL CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

FIGURE  3    PHARMACOGENOMIC BIOMARKERS INFORMATION IN DRUG LABELING

FIGURE  4    PERCENTAGE OF PATIENTS INEFFECTIVE FOR PARTICULAR DRUG (%)

FIGURE  5    LIST OF CLEARED OR APPROVED COMPANION DIAGNOSTIC DEVICES (IMAGING TOOLS AND IN VITRO) BY FDA

FIGURE  6    GLOBAL CANCER BIOMARKER MARKET SHARE BY PROFILING TECHNOLOGY 2018 & 2027 (%)

FIGURE  7    GLOBAL GENOMICS MARKET BY NEXT-GENERATION SEQUENCING (NGS) 2019-2027 ($ MILLION)

FIGURE  8    GLOBAL GENOMICS MARKET BY MICROARRAY 2019-2027 ($ MILLION)

FIGURE  9    GLOBAL GENOMICS MARKET BY POLYMERASE CHAIN REACTION (PCR) 2019-2027 ($ MILLION)

FIGURE  10  GLOBAL PROTEOMICS MARKET BY MASS SPECTROMETRY 2019-2027 ($ MILLION)

FIGURE  11  GLOBAL PROTEOMICS MARKET BY 2D GEL ELECTROPHORESIS 2019-2027 ($ MILLION)

FIGURE  12  GLOBAL PROTEOMICS MARKET BY PROTEIN MICROARRAY TECHNOLOGY 2019-2027 ($ MILLION)

FIGURE  13  GLOBAL PROTEOMICS MARKET BY ANTIBODY ARRAY TECHNOLOGY 2019-2027 ($ MILLION)

FIGURE  14  GLOBAL PROTEOMICS MARKET BY PEPTIDE ARRAY TECHNOLOGY 2019-2027 ($ MILLION)

FIGURE  15  GLOBAL OTHER OMIC TECHNOLOGIES MARKET BY METABOLOMICS 2019-2027 ($ MILLION)

FIGURE  16  GLOBAL OTHER OMIC TECHNOLOGIES MARKET BY GLYCOMICS 2019-2027 ($ MILLION)

FIGURE  17  GLOBAL IMAGING TECHNOLOGIES MARKET BY MAGNETIC RESONANCE IMAGING(MRI) 2019-2027 ($ MILLION)

FIGURE  18  GLOBAL IMAGING TECHNOLOGIES MARKET BY POSITRON EMISSION TOMOGRAPHY (PET) 2019-2027 ($ MILLION)

FIGURE  19  GLOBAL IMAGING TECHNOLOGIES MARKET BY COMPUTED TOMOGRAPHY 2019-2027 ($ MILLION)

FIGURE  20  GLOBAL IMAGING TECHNOLOGIES MARKET BY MAMMOGRAPHY 2019-2027 ($ MILLION)

FIGURE  21  GLOBAL IMAGING TECHNOLOGIES MARKET BY ULTRASOUND 2019-2027 ($ MILLION)

FIGURE  22  GLOBAL IMMUNOASSAYS MARKET BY IMMUNOHISTOCHEMISTRY(IHC) TESTS 2019-2027 ($ MILLION)

FIGURE  23  GLOBAL IMMUNOASSAYS MARKET BY ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 2019-2027 ($ MILLION)

FIGURE  24  GLOBAL IMMUNOASSAYS MARKET BY FLOW CYTOMETRY 2019-2027 ($ MILLION)

FIGURE  25  GLOBAL CYTOGENETICS-BASED TESTS  MARKET BY IN SITU HYBRIDIZATION 2019-2027 ($ MILLION)

FIGURE  26  GLOBAL CYTOGENETICS-BASED TESTS  MARKET BY OTHERS CYTOGENETICS-BASED TESTS 2019-2027 ($ MILLION)

FIGURE  27  GLOBAL CANCER BIOMARKER MARKET SHARE BY BIOMARKER 2018 & 2027 (%)

FIGURE  28  GLOBAL CANCER BIOMARKER MARKET SHARE BY CANCER TYPE 2018 & 2027 (%)

FIGURE  29  GLOBAL CANCER BIOMARKER MARKET SHARE BY CANCER TYPE 2018 & 2027 (%)

FIGURE  30  PORTER’S FIVE FORCE ANALYSIS

FIGURE  31  GLOBAL CANCER BIOMARKER MARKET REGIONAL OUTLOOK 2018 & 2027 (%)

FIGURE  32  THE UNITED STATES CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

FIGURE  33  PROPORTION OF DEATH CAUSED BY CANCER AND OTHER DISEASE IN CANADA (%)

FIGURE  34  CANADA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

FIGURE  35  GERMANY CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

FIGURE  36  THE UNITED KINGDOM CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

FIGURE  37  FRANCE CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

FIGURE  38  ITALY CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

FIGURE  39  SPAIN  CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

FIGURE  40  REST OF EUROPE CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

FIGURE  41  CHINA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

FIGURE  42  INDIA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

FIGURE  43  JAPAN CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

FIGURE  44  SOUTH KOREA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

FIGURE  45  AUSTRALIA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

FIGURE  46  REST OF APAC CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

FIGURE  47  LATIN AMERICA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

FIGURE  48  MIDDLE EAST AND AFRICA CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)

FIGURE  49  MARKET SHARE ANALYSIS OF KEY PLAYERS 2017 (%)

  1. MARKET BY PROFILING TECHNOLOGY
    • OMIC TECHNOLOGY
      • GENOMICS
        • NEXT-GENERATION SEQUENCING (NGS)
        • MICROARRAY
        • POLYMERASE CHAIN REACTION (PCR)
      • PROTEOMICS
        • MASS SPECTROMETRY
        • 2D GEL ELECTROPHORESIS
        • PROTEIN MICROARRAY TECHNOLOGY
        • ANTIBODY ARRAY TECHNOLOGY
        • PEPTIDE ARRAY TECHNOLOGY
      • OTHER OMIC TECHNOLOGIES
        • METABOLOMICS
        • GLYCOMICS
      • IMAGING TECHNOLOGIES
        • MAGNETIC RESONANCE IMAGING (MRI)
        • POSITRON EMISSION TOMOGRAPHY (PET)
        • COMPUTED TOMOGRAPHY
        • MAMMOGRAPHY
        • ULTRASOUND
      • IMMUNOASSAYS
        • IMMUNOHISTOCHEMISTRY (IHC) TESTS
        • ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
        • FLOW CYTOMETRY
      • CYTOGENETIC-BASED TESTS
        • IN SITU HYBRIDIZATION
        • OTHERS CYTOGENETIC-BASED TESTS
  1. MARKET BY BIOMARKER
    • GENETIC BIOMARKERS
    • PROTEIN BIOMARKERS
    • GLYCO BIOMARKERS
  2. MARKET BY CANCER TYPE
    • LUNG CANCER
    • BREAST CANCER
    • COLORECTAL CANCER
    • PROSTATE CANCER
    • STOMACH CANCER
    • OTHERS CANCER TYPE
  3. MARKET BY APPLICATION
    • DIAGNOSTICS
    • DRUG DISCOVERY AND DEVELOPMENT
    • PROGNOSTICS
    • RISK ASSESSMENT
    • OTHER APPLICATION
  4. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • THE UNITED STATES
      • CANADA
    • EUROPE
      • GERMANY
      • THE UNITED KINGDOM
      • FRANCE
      • ITALY
      • SPAIN
      • REST OF EUROPE
    • ASIA PACIFIC
      • CHINA
      • INDIA
      • JAPAN
      • SOUTH KOREA
      • AUSTRALIA
      • REST OF APAC
    • REST OF WORLD
      • LATIN AMERICA
      • MIDDLE EAST AND AFRICA

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.


    Choose License Type

    Buy Now